Evidence map›Paper›PMID 40067377›Full record

ReviewClinical journal of the American Society of Nephrology : CJASN2025

Dietary Intake and Gut Microbiome in CKD.

Julie Ann Kemp, Marcia Ribeiro, Natália A Borges, Ludmila F M F Cardozo, Denis Fouque, Denise Mafra

Abstract readReview
In one paragraph

Review in Clinical journal of the American Society of Nephrology : CJASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Salt and chronic kidney disease.Nature reviews. Nephrology · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julie Ann KempGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Rio de Janeiro, Brazil.ORCID 0000-0001-6739-8832
Marcia RibeiroGraduate Program in Biological Sciences - Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.ORCID 0000-0002-4957-3630
Natália A BorgesGraduate Program in Food, Nutrition and Health - Institute of Nutrition, State University of Rio de Janeiro (UERJ), Rio de Janeiro, Brazil.ORCID 0000-0003-0898-5118
Ludmila F M F CardozoGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Rio de Janeiro, Brazil.ORCID 0000-0001-8507-2369
Denis FouqueDepartment of Nephrology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, INSERM 1060, CENS, Université Claude Bernard Lyon 1, France.ORCID 0000-0002-9707-7199
Denise MafraGraduate Program in Nutrition Sciences, Fluminense Federal University (UFF), Rio de Janeiro, Brazil.ORCID 0000-0001-6752-6056

Funding

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
6 · The paper itself

Abstract

Gut dysbiosis, characterized by an imbalance in the gut microbiota, has emerged as a potential factor influencing CKD progression. This condition plays a crucial role in the gut-kidney axis, where changes in microbial composition can contribute to systemic inflammation and uremic toxin production and ultimately exacerbate kidney damage. Understanding the dynamics of the gut-kidney axis provides new insights into potential therapeutic strategies to mitigate CKD progression. Diet is the primary driver of gut microbiota composition. Therefore, an approach emphasizing healthy nutritional patterns is recommended for improving overall health, cardiovascular disease, and profoundly altered metabolic patterns in patients with CKD. Dietary modifications have been explored as therapeutic strategies targeting the microbiome to improve outcomes in CKD. An emerging therapeutic target is the production of dysmetabolites by the gut microbiota, which may help alleviate uremic and cardiovascular toxicity. In addition, future research should broaden the scope to include other microorganisms, such as fungi, archaea, and viruses. This expanded focus will enable a more comprehensive understanding of the gut-kidney axis and pave the way for more personalized and effective treatment strategies for patients with CKD. This review explores the role of lifestyle, particularly diet, in kidney health; highlights new gut microbiome therapies; and identifies research opportunities in CKD.

Indexed as

DietGastrointestinal MicrobiomeRenal Insufficiency, ChronicDysbiosisHumansKidneyCKDdietgut microbiotanutritionuremic toxins

Identifiers

PMID40067377
PMCPMC12262916

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.